Absci (ABSI) Non-Current Deffered Revenue (2021 - 2026)
Absci (ABSI) reported Non-Current Deffered Revenue of $641000.0 for Q1 2026, up 47.02% sequentially from $436000.0 in Q4 2025.
Absci (ABSI) Non-Current Deffered Revenue (2021 - 2026) Analysis & Trends
Absci (ABSI) has 5 years of Non-Current Deffered Revenue data on file, last reported at $641000.0 in Q1 2026.
- For the quarter ending Q1 2026, Non-Current Deffered Revenue changed N/A year-over-year to $641000.0; the trailing twelve-month figure through Mar 2026 stood at $641000.0 (changed N/A YoY), and the FY2025 full-year result was $436000.0, changed N/A from the prior year.
- Non-Current Deffered Revenue improved to $641000.0 in Q1 2026, from $436000.0 in the prior quarter.
- In the past five years, Non-Current Deffered Revenue ranged from a high of $966000.0 in Q4 2023 to a low of $180000.0 in Q1 2024.
- A 4-year average of $555750.0 and a median of $538500.0 in 2025 frame the typical range for Non-Current Deffered Revenue.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 225.10 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Absci | 1.23 Bn | 1.11 Bn | - | 641,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 641,000.00 |
| Dec 31, 2025 | 436,000.00 |
| Mar 31, 2024 | 180,000.00 |
| Dec 31, 2023 | 966,000.00 |
| Sep 30, 2021 | 122,000.00 |
| Jun 30, 2021 | 839,000.00 |